MX381046B - Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas. - Google Patents

Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.

Info

Publication number
MX381046B
MX381046B MX2017005553A MX2017005553A MX381046B MX 381046 B MX381046 B MX 381046B MX 2017005553 A MX2017005553 A MX 2017005553A MX 2017005553 A MX2017005553 A MX 2017005553A MX 381046 B MX381046 B MX 381046B
Authority
MX
Mexico
Prior art keywords
inhibitors
cancer
referral
treatment
related applications
Prior art date
Application number
MX2017005553A
Other languages
English (en)
Spanish (es)
Other versions
MX2017005553A (es
Inventor
Brian Wong
David Bellovin
Emma Masteller
Julie Hambleton
Katherine E Lewis
Kevin Hestir
Robert Sikorski
Original Assignee
Five Prime Therapeutics Inc
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc, Bristol Myers Squibb Co filed Critical Five Prime Therapeutics Inc
Publication of MX2017005553A publication Critical patent/MX2017005553A/es
Publication of MX381046B publication Critical patent/MX381046B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2017005553A 2014-10-29 2015-10-28 Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas. MX381046B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462072035P 2014-10-29 2014-10-29
US201562157368P 2015-05-05 2015-05-05
US201562192025P 2015-07-13 2015-07-13
PCT/US2015/057781 WO2016069727A1 (en) 2014-10-29 2015-10-28 Combination therapy for cancer

Publications (2)

Publication Number Publication Date
MX2017005553A MX2017005553A (es) 2017-07-04
MX381046B true MX381046B (es) 2025-03-12

Family

ID=54695820

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005553A MX381046B (es) 2014-10-29 2015-10-28 Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.

Country Status (26)

Country Link
US (5) US9765147B2 (enExample)
EP (2) EP3212670B1 (enExample)
JP (3) JP6920989B2 (enExample)
KR (1) KR102636539B1 (enExample)
CN (1) CN107567336B (enExample)
AU (1) AU2015339306B2 (enExample)
BR (1) BR112017008914A2 (enExample)
CA (1) CA2963147A1 (enExample)
CY (1) CY1123957T1 (enExample)
DK (1) DK3212670T3 (enExample)
EA (1) EA036261B1 (enExample)
ES (1) ES2851390T3 (enExample)
HR (1) HRP20210440T1 (enExample)
HU (1) HUE054012T2 (enExample)
IL (1) IL251464B2 (enExample)
LT (1) LT3212670T (enExample)
MX (1) MX381046B (enExample)
PL (1) PL3212670T3 (enExample)
PT (1) PT3212670T (enExample)
RS (1) RS61602B1 (enExample)
SG (1) SG11201702723VA (enExample)
SI (1) SI3212670T1 (enExample)
SM (1) SMT202100164T1 (enExample)
TW (1) TWI711463B (enExample)
WO (1) WO2016069727A1 (enExample)
ZA (1) ZA201702382B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130302322A1 (en) * 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
AU2015210750B2 (en) 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
SI3102605T1 (sl) 2014-02-04 2019-04-30 Pfizer Inc. Kombinacija PD-1 antagonista in VEGFR inhibitorja za zdravljenje raka
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
CN113350501A (zh) * 2014-06-23 2021-09-07 戊瑞治疗有限公司 用结合集落刺激因子1受体(csf1r)的抗体治疗病状的方法
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
AU2015339306B2 (en) 2014-10-29 2021-07-22 Bristol-Myers Squibb Company Combination therapy for cancer
WO2016089873A1 (en) * 2014-12-02 2016-06-09 Celgene Corporation Combination therapies
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
BR112017018234A2 (pt) 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
WO2016176504A1 (en) * 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
JP2018514550A (ja) 2015-04-28 2018-06-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
JP6851322B2 (ja) * 2015-05-27 2021-03-31 ユーシービー バイオファルマ エスアールエル 神経疾患を治療する方法
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
KR20190015407A (ko) * 2016-06-03 2019-02-13 브리스톨-마이어스 스큅 컴퍼니 재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
AU2017306506B2 (en) 2016-08-05 2020-05-21 Y-Biologics Inc. Antibody to programmed cell death 1 (PD-1) and use thereof
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
CN110191721A (zh) 2016-09-26 2019-08-30 集合集团控股公司 有淋巴系统失调的受试者中癌症的评估与治疗方法
WO2018065938A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
CA3040914A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
JP7304287B2 (ja) * 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
ES2863412T3 (es) 2017-03-29 2021-10-11 Shionogi & Co Composición farmacéutica para el tratamiento del cáncer
JP2020517256A (ja) 2017-04-19 2020-06-18 エルスター セラピューティクス， インコーポレイテッド 多重特異性分子およびその使用
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
CA3073531A1 (en) 2017-09-13 2019-03-21 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
CN111655288A (zh) * 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
ES2920283T3 (es) * 2017-12-05 2022-08-02 Progastrine Et Cancers S A R L Terapia de combinación entre un anticuerpo antiprogastrina y la inmunoterapia para tratar el cáncer
EP3720881A1 (en) * 2017-12-08 2020-10-14 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2019139583A1 (en) * 2018-01-10 2019-07-18 Lee Patrice A Methods and combination therapy to treat cancer
CN112423780A (zh) * 2018-03-05 2021-02-26 诗彭斯眼科研究所公司 通过靶向集落刺激因子进行的青光眼和视神经病变的治疗
CN108610422B (zh) * 2018-03-29 2019-05-28 中国人民解放军军事科学院军事医学研究院 抑制pd-1/pd-l1信号通路的结合分子
KR20200139724A (ko) * 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
JP7407452B2 (ja) * 2018-07-31 2024-01-04 国立大学法人北海道大学 がんの治療及び／又は予防のための医薬
WO2020058372A1 (en) * 2018-09-19 2020-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
WO2020227431A1 (en) 2019-05-06 2020-11-12 Brown University Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells
KR20220044904A (ko) * 2019-05-31 2022-04-12 알렉소 온콜로지 인크. 면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법
KR20220062503A (ko) * 2019-08-02 2022-05-17 씨티티큐-아케소 (상하이) 바이오메드. 테크. 컴퍼니, 리미티드 항-pd-1 항체 및 이의 약제학적 용도
CN114845710A (zh) 2019-11-27 2022-08-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
CN114907267A (zh) * 2021-02-08 2022-08-16 中国科学院上海药物研究所 用于抗肿瘤的药物组合
BR112023022774A2 (pt) 2021-05-13 2024-01-02 Alx Oncology Inc Terapias de combinação para tratamento de câncer
WO2025129066A1 (en) * 2023-12-15 2025-06-19 The Regents Of The University Of California Detection, prevention, and reversal of acquired resistance to immune checkpoint blockade therapy

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU2728588A (en) 1987-10-23 1989-05-23 Genetics Institute Inc. Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5866114A (en) 1992-06-09 1999-02-02 Chiron Corporation Crystallization of M-CSFα
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999029345A1 (en) 1997-12-05 1999-06-17 La Jolla Institute For Experimental Medicine Inhibition of tumor growth by macrophage intervention
AU6366999A (en) 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
DE50002293D1 (de) 1999-10-28 2003-06-26 Hofbauer Reinhold Verwendung von csf-1-inhibitoren
WO2001034177A2 (en) 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US6773895B2 (en) 2000-09-01 2004-08-10 Boehringer Ingelheim Pharma Kg Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
US7247618B2 (en) 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CN1787837A (zh) 2002-11-15 2006-06-14 希龙公司 防止和治疗癌转移以及与癌转移相关的骨质损失的方法
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US7807389B2 (en) 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
JP4810427B2 (ja) 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
ES2393555T3 (es) 2003-10-22 2012-12-26 Keck Graduate Institute Métodos para la síntesis de polipéptidos hetero-multiméricos en levaduras usando una estrategia de apareamiento haploide.
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
WO2005070447A2 (en) 2004-01-21 2005-08-04 Chiron Corporation M-csf muteins and uses thereof
AU2005245896A1 (en) 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
CA2574654C (en) 2004-07-22 2014-02-18 Five Prime Therapeutics, Inc. Compositions and methods of use for mgd-csf in disease treatment
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
EP1841874B1 (en) 2005-01-27 2010-01-06 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
PL2161336T5 (pl) * 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
JP2009515521A (ja) 2005-11-10 2009-04-16 レセプター バイオロジックス， インコーポレイテッド レセプターアイソフォームおよびリガンドアイソフォームの産生のための方法
WO2007075933A2 (en) 2005-12-21 2007-07-05 Cell Signaling Technology, Inc. Translocation and mutant csf1r kinase in human leukemia
CA2634945A1 (en) 2005-12-22 2007-10-25 Novartis Ag Soluble human m-csf receptor and uses thereof
EP1984024A2 (en) 2006-01-05 2008-10-29 Novartis AG Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
WO2008060610A2 (en) 2006-11-17 2008-05-22 Biogen Idec Ma Inc. Systemic administration of colony stimulating factors to treat amyloid associated disorders
DE602008004296D1 (de) 2007-02-14 2011-02-17 Vaccinex Inc Humanisierte anti-cd100-antikörper
WO2008124858A2 (en) 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
WO2008150383A1 (en) 2007-05-30 2008-12-11 Albert Einstein College Of Medicine Of Yeshiva University Csf-1r mutants
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
RS56743B1 (sr) 2007-08-21 2018-03-30 Amgen Inc Humani c-fms antigen vezujući proteini
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
AU2008318656A1 (en) 2007-10-31 2009-05-07 Janssen Pharmaceutica N.V. Biomarker for assessing response to FMS treatment
WO2009075344A1 (ja) 2007-12-12 2009-06-18 Japan As Represented By Director General Of Agency Of National Cancer Center M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
CN101970496B (zh) 2008-03-14 2014-04-16 特朗斯吉有限公司 针对csf-1r的抗体
CA2722992A1 (en) * 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
WO2010001617A1 (en) * 2008-07-04 2010-01-07 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2949670B1 (en) 2009-12-10 2019-02-27 F. Hoffmann-La Roche AG Antibodies binding preferentially human csf1r extracellular domain 4 and their use
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
SMT201900074T1 (it) * 2010-05-04 2019-02-28 Five Prime Therapeutics Inc Anticorpi che legano csf1r
CN103261217B (zh) * 2010-11-11 2017-04-26 港大科桥有限公司 可溶性 pd‑1变体、融合构建体及其用途
WO2012082573A1 (en) 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
CA2852800A1 (en) 2011-10-21 2013-04-25 Inserm (Institut National De La Sante Et De La Recherche Medicale) A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system
AU2012324847B2 (en) 2011-10-21 2017-01-12 Transgene Sa Modulation of macrophage activation
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AU2013263076B2 (en) * 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
CN104684582A (zh) 2012-08-31 2015-06-03 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
AU2015339306B2 (en) 2014-10-29 2021-07-22 Bristol-Myers Squibb Company Combination therapy for cancer
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EP3523451A1 (en) 2016-10-06 2019-08-14 Genentech, Inc. Therapeutic and diagnostic methods for cancer
EP3655034A1 (en) 2017-07-21 2020-05-27 Genentech, Inc. Therapeutic and diagnostic methods for cancer

Also Published As

Publication number Publication date
US20230212299A1 (en) 2023-07-06
KR20170074962A (ko) 2017-06-30
EA201790926A1 (ru) 2017-09-29
IL251464B (en) 2022-11-01
SG11201702723VA (en) 2017-05-30
KR102636539B1 (ko) 2024-02-13
JP2023052067A (ja) 2023-04-11
CA2963147A1 (en) 2016-05-06
IL251464B2 (en) 2023-03-01
US20200299392A1 (en) 2020-09-24
JP2020186243A (ja) 2020-11-19
LT3212670T (lt) 2021-02-10
HRP20210440T1 (hr) 2021-04-30
IL251464A0 (en) 2017-05-29
SMT202100164T1 (it) 2021-05-07
US20160152715A1 (en) 2016-06-02
PL3212670T3 (pl) 2021-06-14
US10221244B2 (en) 2019-03-05
US10618967B2 (en) 2020-04-14
EP3212670B1 (en) 2020-12-23
EP3212670A1 (en) 2017-09-06
EA036261B1 (ru) 2020-10-20
CY1123957T1 (el) 2022-05-27
TWI711463B (zh) 2020-12-01
RS61602B1 (sr) 2021-04-29
JP6920989B2 (ja) 2021-08-18
US20190202921A1 (en) 2019-07-04
ES2851390T3 (es) 2021-09-06
AU2015339306B2 (en) 2021-07-22
CN107567336B (zh) 2021-12-31
US11566076B2 (en) 2023-01-31
SI3212670T1 (sl) 2021-03-31
AU2015339306A1 (en) 2017-04-20
TW201628653A (zh) 2016-08-16
DK3212670T3 (da) 2021-03-22
BR112017008914A2 (pt) 2018-01-16
JP2017533912A (ja) 2017-11-16
US20180094067A1 (en) 2018-04-05
PT3212670T (pt) 2021-02-15
MX2017005553A (es) 2017-07-04
HUE054012T2 (hu) 2021-08-30
US9765147B2 (en) 2017-09-19
WO2016069727A1 (en) 2016-05-06
CN107567336A (zh) 2018-01-09
EP3835323A1 (en) 2021-06-16
ZA201702382B (en) 2020-07-29

Similar Documents

Publication Publication Date Title
CY1123957T1 (el) Θεραπεια συνδυασμου για καρκινο
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CO2017010618A2 (es) Anticuerpos contra icos
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX387463B (es) Moléculas de unión a antígeno biespecíficas activadoras de células t y antagonistas de unión al eje de pd-1 y usos de los mismos para el tratamiento de cáncer.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
CL2016001871A1 (es) Anticuerpos humanos para pd-1
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
CR20150316A (es) Compuestos y sus métodos de empleo
UY37018A (es) Inhibidores bicíclicos de pad4
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
CO2018013298A2 (es) Anticuerpos anti-gitr y sus usos.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
UY37017A (es) Inhibidores aza-bencimidazol de pad4
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod